Management of Chemotherapy-Ineligible AML: Beyond HMA Monotherapy

home / clinical-consult / management-of-chemotherapy-ineligible-aml-beyond-hma-monotherapy

Eytan Stein, MD, discusses the management of chemotherapy-ineligible AML, as well as the effect of venetoclax in combination with HMA as a new therapy.

EP. 1: Standard of Care for Newly Diagnosed Adult Patients With AML

Eytan Stein, MD

August 3rd 2021

Eytan Stein, MD, discusses the therapeutic standards of care for newly diagnosed adult patients with acute myeloid leukemia.

EP. 2: Approval of Small Molecular Inhibitors for Patients With AML

Eytan Stein, MD

August 3rd 2021

Dr Stein elaborates on the impact of the approval of small molecule inhibitors for the treatment of acute myeloid leukemia.

EP. 3: First-Line Treatments for Chemotherapy-Ineligible AML

Eytan Stein, MD

August 3rd 2021

An expert explains the first-line treatment options for patients with chemotherapy-ineligible acute myeloid leukemia.

EP. 4: Predictive and Prognostic Factors In Chemotherapy-Ineligible AML

Eytan Stein, MD

August 3rd 2021

Eytan Stein, MD, discusses the predictive and prognostic factors for patients with chemotherapy-ineligible acute myeloid leukemia.

EP. 5: First-Line Treatment Considerations for Chemotherapy-Ineligible AML

Eytan Stein, MD

August 3rd 2021

An expert lists the information physicians consider when choosing a first-line therapy for patients with chemotherapy-ineligible acute myeloid leukemia.

EP. 6: Practical Considerations for Venetoclax Plus HMA for Chemotherapy-Ineligible AML

Eytan Stein, MD

August 3rd 2021

Dr Stein elaborates on some practical considerations for the use of venetoclax and hypomethylating agents for the treatment of patients with chemotherapy-ineligible acute myeloid leukemia.